Pharmaceutical company · AZN

AstraZeneca
clinical trial
pipeline

Registry checked

Published

Oncology is the largest mapped primary therapeutic group, with 284 of 564 active trials. This ranking covers mapped groups only. Durvalumab is linked to 42 distinct active studies, with 1 Phase 1, 12 Phase 2, 26 Phase 3, 1 Phase 4, 2 without a recorded phase. Trastuzumab Deruxtecan is linked to 17 distinct active studies, with 2 Phase 1, 5 Phase 2, 7 Phase 3, 1 Phase 4, 2 without a recorded phase.

120 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

564active trials
as lead sponsor
  • Phase 160
  • Phase 2130
  • Phase 3197
  • Phase 415
  • Phase not recorded162

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

7447 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved later by 161 days

2027-08-16 (estimated)2028-01-24 (estimated)
16 Aug 202724 Jan 2028

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945 · ClinicalTrials.gov
Recorded by ComplyRx
31 Oct 2026
Registry last updated
30 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-021210042
2026-10-031000122
2026-10-040000000
2026-10-051110031
2026-10-063220186
2026-10-070000000
2026-10-080100121
2026-10-093100154
2026-10-100100011
2026-10-110000000
2026-10-120000000
2026-10-131210043
2026-10-142200042
2026-10-152410074
2026-10-1662211127
2026-10-170001011
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-212211064
2026-10-222110043
2026-10-230000000
2026-10-241110032
2026-10-250000000
2026-10-260000000
2026-10-271110031
2026-10-280000000
2026-10-290200022
2026-10-300100011
2026-10-310100121
Type totals262712367447 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Durvalumab

Imfinzi

42
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 212
  • Phase 326
  • Phase 41
  • Phase not recorded2
Studied condition
Advanced Hepatocellular Carcinoma · Biliary Tract Cancer · Biliary Tract Neoplasms
Next primary completion
30 November 2026 · estimated
Open drug

Trastuzumab Deruxtecan

Enhertu

17
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 12
  • Phase 25
  • Phase 37
  • Phase 41
  • Phase not recorded2
Studied condition
Adenocarcinoma (NOS) · Advanced or Metastatic Breast Cancer · Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Next primary completion
10 February 2027 · estimated
Open drug

Acalabrutinib

calquence

16
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 27
  • Phase 37
  • Phase 41
  • Phase not recorded0
Studied condition
Chronic Lymphocytic Leukaemia · Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia (CLL)
Next primary completion
15 February 2027 · estimated
Open drug

Datopotamab Deruxtecan

datroway

15
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 22
  • Phase 312
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced or Metastatic NSCLC · Biliary Tract Cancer · Breast Cancer
Next primary completion
11 January 2027 · estimated
Open drug

Olaparib

lynparza

12
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 22
  • Phase 38
  • Phase 41
  • Phase not recorded0
Studied condition
Advanced Ovarian Cancer · BRCA Mutated · BRCA Mutation
Next primary completion
06 April 2027 · estimated
Open drug

Volrustomig

Canonical investigational asset

12
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 13
  • Phase 25
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Clear Cell Renal Cell Carcinoma · Advanced Renal Cell Carcinoma · Biliary Tract Cancer
Next primary completion
30 June 2027 · estimated
Open drug

402 of 564 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 402 of 564 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

AstraZeneca trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
LAVENDER
Anifrolumab

NCT06015737

Phase 3 · Active, not recruiting

Trial source and qualifications

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

5 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 29 Jun 2024 · actual
    Primary completion: 02 Nov 2026 · estimated
    Study completion: 10 Aug 2027 · estimated

    2021202220232024202520262027202820292030
    ANDROMEDA
    AZD9750

    NCT07336446

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    4 candidate observations · 3 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

    • pc date moved · Recorded 2026-10-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • status flip · Recorded 2026-10-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • enrollment change · Recorded 2026-10-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 27 Jan 2026 · actual
    Primary completion: 05 Nov 2026 · estimated
    Study completion: 05 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
    Sonesitatug Vedotin

    NCT06219941

    Phase 2 · Recruiting

    Trial source and qualifications

    AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

    5 candidate observations · 1 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    4 inspected observations omitted. At most three verified observations are shown, not full history.

    • pc date moved · Recorded 2026-07-29 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 13 Dec 2023 · actual
    Primary completion: 17 Nov 2026 · estimated
    Study completion: 28 Jun 2027 · estimated

    2021202220232024202520262027202820292030
    APOLLO
    AZD0754

    NCT06267729

    Phase 2 · Recruiting

    Trial source and qualifications

    Study of AZD0754 in Participants With Metastatic Prostate Cancer

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

    4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    4 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 12 Mar 2024 · actual
      Primary completion: 24 Nov 2026 · estimated
      Study completion: 24 Nov 2026 · estimated

      2021202220232024202520262027202820292030
      TREMENDOUS-2
      Durvalumab

      NCT07081633

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

      3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      3 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 05 Aug 2025 · actual
        Primary completion: 30 Nov 2026 · estimated
        Study completion: 31 Dec 2028 · estimated

        2021202220232024202520262027202820292030
        ECU-NMO-304
        eculizumab

        NCT06724809

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

        4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        4 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 16 Jan 2025 · actual
          Primary completion: 07 Dec 2026 · estimated
          Study completion: 07 Dec 2026 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 189 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 115 actual primary completions, 0 untyped primary completions, 15 past estimates, 8 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          284

          active trials in Oncology

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Oncology284 trials
          • Respiratory30 trials
          • Immunology & Inflammation25 trials
          • Cardiovascular23 trials
          • Metabolic/Endocrine/Nutrition21 trials
          • Renal & Urology15 trials
          • Neurology14 trials
          • Infectious Disease8 trials
          • Gastroenterology & Hepatology5 trials
          • ENT & Hearing4 trials
          • Haematology4 trials
          • Ophthalmology1 trials
          • Unmapped120 trials
          • Healthy volunteers10 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies
          I

          Incyte

          Shared indexed programme context · 1 selected asset

          M

          Merck

          Shared indexed programme context · 1 selected asset

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 4,169 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: AstraZeneca. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          4,169 distinct registry candidates produced 4,169 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 3 unverified, 3 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          3,244 scoped records have indexed enrichment and 925 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T19:17:38.097Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 70feada4a749c1e7702dda71ed8cf3d24e557bbf8cb1a3297691df0e9cf7839a.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 4,169 mapped lead-sponsored clinical studies across all statuses. 3,244 have indexed enrichment, 925 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.